Bristol-Myers Squibb (BMY) Price & Analysis

Compare

11,566 Followers

BMY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$41.20 - $63.33

Previous CloseN/A

Volume3.98M

Average Volume (3M)12.66M

Market Cap

$96.34B

Enterprise Value$134.85B

Total Cash (Recent Filing)$11.78B

Total Debt (Recent Filing)$51.24B

Price to Earnings (P/E)17.8

Beta0.17

Next Earnings

Jul 31, 2025

EPS Estimate

1.06

Last Dividend Ex-Date

Jul 03, 2025

Dividend Yield5.24%

Share Statistics

EPS (TTM)1.80

Shares Outstanding2,035,080,800

10 Day Avg. Volume11,222,469

30 Day Avg. Volume12,657,823

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)5.42

Price to Sales (P/S)0.00

P/FCF Ratio7.21

Enterprise Value/Market Cap1.40

Enterprise Value/Revenue0.71

Enterprise Value/Gross Profit4.29

Enterprise Value/Ebitda4.57

Forecast

1Y Price Target

$55.40

Price Target Upside19.32% Upside

Rating ConsensusHold

Number of Analyst Covering20

Bulls Say, Bears Say

Bulls Say

Commercial ActivitiesManagement is stepping up commercial activities for Cobenfy.

Market OpportunityThere is a significant market opportunity with over 7 million patients with Alzheimer's disease in the US, and no approved therapy for Alzheimer's Disease Psychosis.

Prescriber InterestNew prescribers trying out the drug continue to increase, indicating growing interest.

Bears Say

Alzheimer's Disease Trial ConcernsIf Cobenfy fails in Alzheimer's Disease Psychosis, there is a potential downside in shares of more than 5%.

Prescription TrendsUS prescription trends for Cobenfy have slowed.

Revenue ExpectationsCobenfy scripts are expected to miss Visible Alpha consensus estimates for 2Q25 revenue.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.05% Insiders

23.07% Mutual Funds

0.81% Other Institutional Investors

50.89% Public Companies and Individual Investors

Detailed Ownership Overview >

BMY FAQ

What was Bristol-Myers Squibb’s price range in the past 12 months?

Bristol-Myers Squibb lowest stock price was $41.20 and its highest was $63.33 in the past 12 months.

What is Bristol-Myers Squibb’s market cap?

Bristol-Myers Squibb’s market cap is $96.34B.

When is Bristol-Myers Squibb’s upcoming earnings report date?

Bristol-Myers Squibb’s upcoming earnings report date is Jul 31, 2025 which is in 15 days.

How were Bristol-Myers Squibb’s earnings last quarter?

Bristol-Myers Squibb released its earnings results on Apr 24, 2025. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.495 by $0.305.

Is Bristol-Myers Squibb overvalued?

According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bristol-Myers Squibb pay dividends?

Bristol-Myers Squibb pays a Quarterly dividend of $2.46 which represents an annual dividend yield of 5.24%. See more information on Bristol-Myers Squibb dividends here

What is Bristol-Myers Squibb’s EPS estimate?

Bristol-Myers Squibb’s EPS estimate is 1.06.

How many shares outstanding does Bristol-Myers Squibb have?

Bristol-Myers Squibb has 2,035,080,800 shares outstanding.

What happened to Bristol-Myers Squibb’s price movement after its last earnings report?

Bristol-Myers Squibb reported an EPS of $1.8 in its last earnings report, beating expectations of $1.495. Following the earnings report the stock price went up 0.334%.

Which hedge fund is a major shareholder of Bristol-Myers Squibb?

Currently, no hedge funds are holding shares in BMY

Bristol-Myers Squibb Stock Smart Score

Neutral

Fundamentals

Return on Equity

31.99%

Trailing 12-Months

Asset Growth

-6.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bristol-Myers Squibb

Bristol-Myers Squibb (BMY) is a global biopharmaceutical company headquartered in New York City. It is dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company focuses on therapeutic areas such as oncology, cardiovascular, immunoscience, and fibrosis. Key products include Opdivo and Yervoy in oncology, Eliquis for cardiovascular conditions, and Orencia for immunoscience.

BMY Company Deck

BMY Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call showed strong financial performance and successful product launches, which were slightly overshadowed by disappointing clinical trial results and challenges related to the regulatory environment and Medicare Part D redesign.Read More>

BMY Revenue Breakdown

70.61% U.S.

27.33% International

2.06% Other

BMY Stock 12 Month Forecast

Average Price Target

$55.40

▲(19.32%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","42":"$42","51":"$51","60":"$60","69":"$69"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,42,51,60,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.89,48.51384615384615,50.137692307692305,51.761538461538464,53.385384615384616,55.00923076923077,56.63307692307692,58.25692307692307,59.88076923076923,61.504615384615384,63.128461538461536,64.7523076923077,66.37615384615384,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.89,47.54461538461538,48.199230769230766,48.853846153846156,49.50846153846154,50.16307692307692,50.817692307692305,51.472307692307695,52.12692307692308,52.78153846153846,53.43615384615384,54.09076923076923,54.745384615384616,{"y":55.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.89,45.89846153846154,44.90692307692308,43.91538461538462,42.923846153846156,41.932307692307695,40.940769230769234,39.949230769230766,38.957692307692305,37.966153846153844,36.97461538461538,35.98307692307692,34.99153846153846,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.85,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":47.7,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50.52,"date":1727740800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":52.46,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >